Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6431465 | 1.00 | CPB2 (0.31) | CPB2 | |
| SCHEMBL6431601 | 1.00 | CPB2 (0.31) | CPB2 | |
| SCHEMBL6431598 | 0.93 | CPB2 (0.31) | CPB2 | |
| SCHEMBL6431611 | 0.93 | CPB2 (0.31) | CPB2 | |
| SCHEMBL6431325 | 0.93 | CPB2 (0.31) | CPB2 | |
| SCHEMBL17872153 | 0.76 | CPB2 (0.44) | CPB2 | |
| SCHEMBL17872154 | 0.76 | CPB2 (0.44) | CPB2 | |
| SCHEMBL5495188 | 0.74 | CPB2 (0.34) | CPB2 | |
| SCHEMBL21027658 | 0.69 | CPB2 (0.45) | CPB2 | |
| SCHEMBL21027157 | 0.67 | CPB2 (0.37) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1251827-B1 | NASALLY ADMINISTRABLE ANTIFUNGAL CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2004-05-26 | — | — | EP | disclosed |
| EP-1251827-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | Basilea Pharmaceutica AG (CH) | 2002-10-30 | — | — | EP | disclosed |
| US-20010038824-A1 | Intranasal cyclic peptide formulations | BASILEA PHARMACEUTICA AG (CH) | 2001-11-08 | — | — | US | disclosed |
| WO-2001052894-A2 | NASALLY ADMINISTRABLE CYCLIC PEPTIDE COMPOSITIONS | BASILEA PHARMACEUTICA AG (CH) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010038824-A1 | Intranasal cyclic peptide formulations | VIP, NPPA, SSTR5 | CPB2 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.